Want to see SXTP full AI Analyst Report?
SXTP Stock Chart & Stats
$1.48
$0.07(4.73%)
At close: 4:00 PM EDT
$1.48
$0.07(4.73%)
Day’s Range― - ―
52-Week Range$1.02 - $8.62
Previous CloseN/A
Volume4.03K
Average Volume (3M)199.18K
Market Cap
$3.97M
Enterprise Value$13.28
Total Cash (Recent Filing)$1.02M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Nov 12, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.05
Shares Outstanding3,516,988
10 Day Avg. Volume488,900
30 Day Avg. Volume199,179
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.35
P/FCF Ratio-0.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.70Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.3
Revenue Forecast (FY)$900.00K
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue growth indicates improving commercial traction for the company’s malaria products. Sustained top-line expansion could improve operating leverage over time if distribution broadens and customer demand continues to develop.
Debt-Free Balance SheetThe absence of total debt limits interest obligations and reduces refinancing pressure. This gives management greater flexibility to direct available capital toward commercialization and clinical development, although ongoing losses still create funding needs.
Differentiated Malaria Product And PipelineA differentiated prophylaxis profile may support durable positioning in travel medicine, while the babesiosis program offers an additional indication. Successful clinical and regulatory execution could expand the addressable market beyond malaria prevention.
Bears Say
Severe UnprofitabilityLosses remain extremely large relative to revenue, showing that the current cost structure overwhelms gross profit. Without substantial revenue growth or expense reductions, the company may struggle to achieve sustainable operating leverage and profitability.
Persistent Cash BurnNegative operating and free cash flow means the business is not self-funding its operations or development programs. Continued reliance on external capital increases financing risk and could constrain investment if capital markets become less accessible.
Financing Dependence And Dilution RiskThe small capital raise, expanded equity plan and authorized reverse split indicate continuing dependence on equity financing. Future fundraising may dilute existing holders and reflects limited internal funding capacity while losses and development costs persist.
60 Degrees Pharmaceuticals, Inc. News
SXTP FAQ
What was 60 Degrees Pharmaceuticals, Inc.’s price range in the past 12 months?
60 Degrees Pharmaceuticals, Inc. lowest stock price was $1.02 and its highest was $8.62 in the past 12 months.
What is 60 Degrees Pharmaceuticals, Inc.’s market cap?
60 Degrees Pharmaceuticals, Inc.’s market cap is $3.97M.
When is 60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date?
60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 83 days.
How were 60 Degrees Pharmaceuticals, Inc.’s earnings last quarter?
60 Degrees Pharmaceuticals, Inc. released its earnings results on Aug 14, 2026. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.735 by -$0.165.
Is 60 Degrees Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts 60 Degrees Pharmaceuticals, Inc.’s price is currently Undervalued.
Does 60 Degrees Pharmaceuticals, Inc. pay dividends?
60 Degrees Pharmaceuticals, Inc. does not currently pay dividends.
What is 60 Degrees Pharmaceuticals, Inc.’s EPS estimate?
60 Degrees Pharmaceuticals, Inc.’s EPS estimate is -0.73.
How many shares outstanding does 60 Degrees Pharmaceuticals, Inc. have?
60 Degrees Pharmaceuticals, Inc. has 3,516,988 shares outstanding.
What happened to 60 Degrees Pharmaceuticals, Inc.’s price movement after its last earnings report?
60 Degrees Pharmaceuticals, Inc. reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.735. Following the earnings report the stock price went up 1.271%.
Which hedge fund is a major shareholder of 60 Degrees Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SXTP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
SXTP Stock 12 Month Forecast
Average Price Target
$3.70
▲(150.00% Upside)
Technical Analysis
Ownership Overview
0.69% Insiders
0.25% Mutual Funds
7.96% Other Institutional Investors
91.10% Public Companies and
Individual Investors